Skip to content
Therapy But Better – Lifestyle
Author:
Alebund Pharmaceuticals
Alebund’s AP301 NDA Accepted for Review by China’s NMPA
August 7, 2026
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
July 21, 2026
Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
June 29, 2026